Charles D Smith

Dr. Charles D Smith


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
KFKevin J. French
Kevin J. French
YZYan Zhuang
Yan Zhuang
LMLynn W. Maines
Lynn W. Maines
PGPeng Gao
Peng Gao
WWWenxue Wang
Wenxue Wang
CSCharles D Smith
Charles D Smith
Sphingolipid-metabolizing enzymes control the dynamic balance of the cellular levels of important bioactive lipids, including the apoptotic compound ceramide and the proliferative compound sphingosine 1-phosphate (S1P). Many growth factors and inflammatory cytokines promote the cleavage of sphingomyelin and ceramide leading to rapid elevation of S1P levels through the action of sphingosine kinases (SK1 and SK2). SK1 and SK2 are overexpressed in a variety of human cancers, making these enzymes potential molecular targets for cancer therapy. We have identified an aryladamantane compound, termed ABC294640 [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], that selectively inhibits SK2 activity in vitro, acting as a competitive inhibitor with respect to sphingosine with a Ki of 9.8 μM, and attenuates S1P formation in intact cells. In tissue culture, ABC294640 suppresses the proliferation of a broad panel of tumor cell lines, and inhibits tumor cell migration concomitant with loss of microfilaments. In vivo, ABC294640 has excellent oral bioavailability, and demonstrates a plasma clearance half-time of 4.5 h in mice. Acute and chronic toxicology studies indicate that ABC294640 induces a transient minor decrease in the hematocrit of rats and mice; however, this normalizes by 28 days of treatment. No other changes in hematology parameters, or gross or microscopic tissue pathology, result from treatment with ABC294640. Oral administration of ABC294640 to mice bearing mammary adenocarcinoma xenografts results in dose-dependent antitumor activity associated with depletion of S1P levels in the tumors and progressive tumor cell apoptosis. Therefore, this newly developed SK2 inhibitor provides an orally available drug candidate for the treatment of cancer and other diseases.

15 September 2003
Verified
Journal Article
Closed access
KFKevin J French
Kevin J French
RSRandy S Schrecengost
Randy S Schrecengost
BLBrian D Lee
Brian D Lee
YZYan Zhuang
Yan Zhuang
SSStaci N Smith
Staci N Smith
CSCharles D Smith
Charles D Smith

14 August 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CBCarolyn D. Britten
Carolyn D. Britten
EGElizabeth Garrett-Mayer
Elizabeth Garrett-Mayer
SCSteven H. Chin
Steven H. Chin
KSKeisuke Shirai
Keisuke Shirai
BOBesim Ogretmen
Besim Ogretmen
MTMelanie B. Thomas
Melanie B. Thomas
Purpose: Sphingosine kinases (SK1 and SK2) regulate tumor growth by generating the mitogenic and proinflammatory lipid sphingosine 1-phosphate (S1P). This phase I study investigated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABC294640, a first-in-class orally available inhibitor of SK2. Experimental Design: Escalating doses of ABC294640 were administered orally to patients with advanced solid tumors in sequential cohorts at the following dose levels: 250 mg qd, 250 mg bid, 500 mg bid, and 750 mg bid, continuously in cycles of 28 days. Serial blood samples were obtained to measure ABC294640 concentrations and sphingolipid profiles. Results: Twenty-two patients were enrolled, and 21 received ABC294640. The most common drug-related toxicities were nausea, vomiting, and fatigue. Among the 4 patients at 750 mg bid, one had dose-limiting grade 3 nausea and vomiting, and 2 were unable to complete cycle 1 due to diverse drug-related toxicities. The 500 mg bid dose level was established as the recommended phase II dose. ABC294640 administration resulted in decreases in S1P levels over the first 12 hours, with return to baseline at 24 hours. The best response was a partial response in a patient with cholangiocarcinoma at 250 mg qd, and stable disease was observed in 6 patients with various solid tumors across dose levels. Conclusions: At 500 mg bid, ABC294640 is well tolerated and achieves biologically relevant plasma concentrations. Changes in plasma sphingolipid levels may provide a useful pharmacodynamic biomarker for ABC294640. Clin Cancer Res; 23(16); 4642–50. ©2017 AACR.

4 December 2007 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
LMLynn Maines
Lynn Maines
LFLeo R. Fitzpatrick
Leo R. Fitzpatrick
KFKevin J. French
Kevin J. French
YZYan Zhuang
Yan Zhuang
ZXZuping Xia
Zuping Xia
CSCharles D Smith
Charles D Smith

8 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
CLClayton S Lewis
Clayton S Lewis
CVChristina Voelkel-Johnson
Christina Voelkel-Johnson
CSCharles D Smith
Charles D Smith
Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640

1 December 2015 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
RSRandy S. Schrecengost
Randy S. Schrecengost
SKStaci N. Keller
Staci N. Keller
MSMatthew J. Schiewer
Matthew J. Schiewer
KKKaren E. Knudsen
Karen E. Knudsen
CSCharles D Smith
Charles D Smith
The bioactive sphingolipid sphingosine-1-phosphate (S1P) drives several hallmark processes of cancer, making the enzymes that synthesize S1P, that is, sphingosine kinase 1 and 2 (SK1 and SK2), important molecular targets for cancer drug development. ABC294640 is a first-in-class SK2 small-molecule inhibitor that effectively inhibits cancer cell growth in vitro and in vivo. Given that AR and Myc are two of the most widely implicated oncogenes in prostate cancer, and that sphingolipids affect signaling by both proteins, the therapeutic potential for using ABC294640 in the treatment of prostate cancer was evaluated. This study demonstrates that ABC294640 abrogates signaling pathways requisite for prostate cancer growth and proliferation. Key findings validate that ABC294640 treatment of early-stage and advanced prostate cancer models downregulate Myc and AR expression and activity. This corresponds with significant inhibition of growth, proliferation, and cell-cycle progression. Finally, oral administration of ABC294640 was found to dramatically impede xenograft tumor growth. Together, these pre-clinical findings support the hypotheses that SK2 activity is required for prostate cancer function and that ABC294640 represents a new pharmacological agent for treatment of early stage and aggressive prostate cancer. Implications: Sphingosine kinase inhibition disrupts multiple oncogenic signaling pathways that are deregulated in prostate cancer. Mol Cancer Res; 13(12); 1591–601. ©2015 AACR.